Millipore Expands Analytical Services for Biologics
Millipore Bioscience’s Drug Discovery Services unit has been among the company’s fastest-growing businesses recently. This purchase grows the business and expands it internationally. BioAnaLab was founded in 2002 as a University of Oxford spin out. According to Hygea VCT, for the fiscal year ended October 2007, BioAnaLab revenues increased 59.0% to £1.84 million ($2.45 million = €0.75 = $1) and pre-tax profit more than doubled to £240,000 ($320,000).
Billerica, MA 8/10/09—Millipore has acquired BioAnaLab, a service provider that specializes in the analysis of biologic drugs and vaccines, for an undisclosed amount. Based in Oxford, UK, BioAnaLab’s service offerings include assay transfer/development, validation and sample analysis, pharmacokinetics/toxicokinetics, immunogenicity, biological potency and vaccine services. Millipore stated that the acquisition expands its biopharmaceutical services business into Europe. “BioAnaLab will add cGMP support testing capabilities to our portfolio, a solid customer base, and a team of highly talented services professionals with expertise in emerging scientific disciplines,” stated Jonathan DiVincenzo, president of Millipore’s Bioscience Division. BioAnaLab founder and CEO Geoff Hale, PhD, will become director of Biopharma Services in Europe for Millipore’s Bioscience Division.
